Syndax Pharmaceuticals Inc cotiza a 13.71 USD y tiene una capitalización bursátil de $1.2B. En los últimos 12 meses ha facturado $252M con un margen de flujo de caja libre del -187.5%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating fac…
| Métrica | SNDX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -158.4% | -38.6% | -119.8% |
| Net Margin | -165.6% | -33.6% | -132.0% |
| FCF Margin | -187.5% | -13.9% | -173.6% |
| ROE | -441.6% | -40.4% | -401.2% |
| ROA | -53.9% | -32.0% | -21.9% |
| Current Ratio | 4.40 | 2.84 | +1.56 |
| Debt / Equity | — | 0.28 | — |